Compare · ABSI vs SLGC
ABSI vs SLGC
Side-by-side comparison of Absci Corporation (ABSI) and SomaLogic Inc. (SLGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and SLGC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- ABSI is the larger of the two at $1.50B, about the same size as SLGC ($1.43B).
- ABSI has hit the wire 6 times in the past 4 weeks while SLGC has been quiet.
- ABSI has more recent analyst coverage (21 ratings vs 6 for SLGC).
- Company
- Absci Corporation
- SomaLogic Inc.
- Price
- -
- -
- Market cap
- $1.50B
- $1.43B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2021
- News (4w)
- 6
- 0
- Recent ratings
- 21
- 6
ABSI
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Latest ABSI
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- CFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,320 shares, decreasing direct ownership by 2% to 483,144 units (SEC Form 4) (withholding obligation)
- Absci to Participate in Upcoming Investor Conferences
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- SEC Form 10-Q filed by Absci Corporation
Latest SLGC
- OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form 15-12G filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- Taich Adam returned 48,425 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Ryan Jason
- Roelke Alison Marie returned 17,143 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Post Richard A returned 57,430 shares to the company, closing all direct ownership in the company (SEC Form 4)